Dendreon and Johnson & Johnson enter cancer deal

DNDN and JNJ company The R.W. Johnson Pharmaceutical Research Institute will develop immunotherapies, including dendritic cell-based vaccine therapy to treat a variety of cancers. DNDN will receive fi...